Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Easy to accumulate
Here is the release
Dow Jones
08/23/2021 07:00 AM ET
* Press Release: Khiron Reports Q2 Results, 47% QoQ Increase in Medical Cannabis Revenues Driven by Colombia and Germany
Khiron Reports Q2 Results, 47% QoQ Increase in Medical Cannabis Revenues Driven by Colombia and Germany
PR Newswire
TORONTO, Aug. 23, 2021
-- Q2 2021 revenues of $2.8 million, up 68% YoY
-- Medical cannabis revenues reach $825,500, up 47% sequentially, with sales
in Colombia, Germany, UK, and Peru contributing to gross medical cannabis
profit margin of 88%
-- European medical cannabis sales growth of 280% sequentially, representing
over 25% of total medical cannabis revenues
-- Medical cannabis expected to become dominant revenue stream, with monthly
revenues forecast to increase to over $1 million by Q1 2022, on top of
expected $1 million in health services
-- $9.4 million in cash as of June 30,2021, a decrease of $3.2 million from
march 31st 2021, and proforma Q2 2021 cash balance of $20.6 million,
including estimated net proceeds from the Company's July 2021 offering
TORONTO, Aug. 23, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, today announces its financial results for the quarter ended June 30, 2021. These filings are available for review on the Company's SEDAR profile at www.sedar.com. All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.
Summary of Key Financial Results
3 Months 3 Months 3 Months
ended Jun ended Jun ended Mar
Canadian dollars 30 2021 30 2020 31 2021
$ $ $
Revenues ('000s) 2,803 1,670 2,837
Medical Cannabis 826 25 563
Gross profit before fair value adjustments
('000s) 1,046 319 1,090
General and administrative costs ('000s) 4,428 4,531 5,592
Net loss ('000s) (4,796) (5,713) (5,494)
Adjusted EBITDA (1) ('000s) (3,850) (3,855) (4,019)
Net loss per share (basic and diluted) (0.03) (0.05) (0.04)
Weighted average shares outstanding ('000s) 151,027 116,546 150,718
(1) Adjusted EBITDA (earnings before interest, taxes, depreciation and
amortization or in this case loss) is a non-International Financial
Reporting Standards ("IFRS") measure calculated as net loss before tax as
reported under IFRS and adding back share-based compensation expense,
transaction fees, unrealized gain on changes in fair value of biological
assets, depreciation and non-recurring items. Refer to the "Non-IFRS
Measures" note below for further information and the Company's MD&A for a
reconciliation.
Key Operating Statistics
3 Months 3 Months 3 Months
ended Jun ended Jun ended Mar
30 2021 30 2020 31 2021
Medical Cannabis
Revenue generating countries (#) 4 1 4
Latin America (Units) 11,058 380 7,969
Europe (Grams) 42,890 N/A 11,080
Health Services
Patient interactions (#) 32,984 19,151 32,331
Wellness
Units (#) 3173 3,064 2,758
Management Commentary
"In Q2, we continued to achieve strong results within our Medical Cannabis segment, reporting 47% sequential growth and margins of over 85% for the fourth consecutive quarter. With revenues increasing across all markets, our medical cannabis segment contributed 29% of revenues and 70% of gross profits, showcasing how our medical cannabis business can fundamentally shift margin profiles as revenues increase," comments Alvaro Torres, Chief Executive Officer and Director of the Company.
Mr. Torres continues, "In Q2 and subsequently, we achieved a number of very significant milestones. With the start of sales in Brazil in July, our sales presence has expanded to five of our six target markets. In addition, we are making strides toward launching our Zerenia(TM) clinics in Mexico this year, and recently expedited our entry into Mexico by several months with the receipt of a high-THC extract export quota from Colombia. We continue to expand patient access within our core markets, partnering with the Colombia Cancer League and 21 leading medical institutions to deliver 3,000 medical cannabis consultations at no cost to patients. In June, we also opened our first clinic outside of Colombia in Lima, Peru, which is expected to have a positive impact on prescription volumes going forward. Finally, in Europe we expanded our product offerings in both the UK and Germany, and delivered our largest shipment to date, resulting in a significant revenue contribution from Europe during the second quarter."
"With these milestones behind us, we expect to increase sales of medical cannabis products across all markets over the coming 12 months. As we continue to expand our clinic and patient networks, partnerships with insurance providers, and distribution channels, we anticipate that global medical cannabis revenues will reach $1 million per month by Q1 2022. In addition, we anticipate that revenues from Health Services will stabilize at $1 million per month, consistent with levels achieved in March 2021," continued Alvaro Torres.
Q2 2021 operating highlights and subsequent events
-- Medical cannabis revenues increased 47% from the prior quarter, reaching
over $825,000; in total, medical cannabis products contributed 29% of
total revenues and 70% of gross profits.
-- Driven by growth in medical cannabis, the Company achieved a gross profit
margin (before fair market value adjustments) of 37%, or $1.0 million,
reflecting a 228% improvement over the prior year.
Latin America
-- Insurance coverage in Colombia continues to be a catalyst for growth,
with more than 10,600 prescriptions filled in Q2 2021, a 40% increase
from Q1 2021. The percentage of prescriptions issued in Colombia and
covered by insurance also increased from over 40% in Q4 2020 to over 50%
in Q2 2021.
-- Returning medical cannabis patients in Colombia reached nearly 50% in Q2
2021, providing a more stable Medical Cannabis revenue base.
-- With more than 24,000 prescriptions filled year-to-date in Latin America
and continued month-over-month growth, Q3 2021 continues to build on Q2
2021 levels.
-- In June 2021, the Company opened its first Zerenia(TM) clinic outside of
Colombia, in Lima, Peru, a city of over 10 million and home to a third of
the country.
-- In June 2021, Khiron was awarded high-THC medical cannabis quotas for
exports to Mexico from Colombia.
-- In July 2021, Khiron successfully exported medical cannabis into Brazil
under an import authorization from the Brazilian health authority,
ANVISA. Also, Dr. Eduardo Faveret was appointed Medical Director for
Khiron Brazil, positioning the Company to expand its Zerenia(TM) clinics
in key cities in Brazil.
-- Khiron recently partnered with the Colombia Cancer League to deliver an
additional 3,000 medical cannabis patient consultations during the month
of June, in collaboration with 21 leading medical institutions in 11
cities throughout Colombia.
Europe
-- Q2 2021 sales in the UK and Germany increased significantly, up 475% and
265%, respectively, from the prior quarter, driven by expanded medical
cannabis products lines and increased product availability. As a result,
Europe accounted for over 25% of Q2 medical cannabis sales.
-- In the UK, the Company's medical cannabis e-learning certification,
Khiron Academy, received accreditation for Continuing Professional
Development credits in the UK.
-- In Q2 2021, the Company recorded gross profits for European medical
cannabis of $214,573, representing a gross margin of 100% thanks to our
business strategy in that region
Discussion of Operations for the Three Months Ending June 30, 2021
During the second quarter of 2021, the Company reported revenues of $2.8 million, a 68% increase as compared to Q2 2020 due to normalized clinic operations and the growth of medical cannabis sales. Relative to Q1 2021, second quarter revenues were relatively consistent as a result of a 13% decline in Health Services revenues, offset by a 47% increase in Medical Cannabis Product sales, which reached $825,500 in the quarter, as the Company benefited from significant growth in Europe and a growing patient base in Colombia. While health services were impacted by rising COVID-19 cases and foreign exchange rates during the quarter, clinic revenues are expected to stabilize at $1 million per month, consistent with March 2021 levels.
At $1.0 million, or 37% of revenues, the Company's gross profits benefited from increasing Medical Cannabis Product sales, which offset margin compression within Health Services. Medical cannabis margins remained high at 88% of revenues, while health service margins decreased quarter-over-quarter to 15% of revenues, as a result of geo-political events and a surge of COVID-19 cases in Colombia which impacted clinic volumes and service mix. Q2 2021 health services margins were consistent with prior year levels.
Overall, the Company recorded a net loss of $4.8 million in the second quarter, which compares to a net loss of $5.7 million in the prior year and $5.5 million in the prior quarter. Adjusted EBITDA losses for Q2 2021 were $3.9 million, compared to the prior quarter loss of $4.0 million and prior year loss of $3.9 million.
(MORE TO FOLLOW) Dow Jones Newswires
August 23, 2021 07:00 ET (11:00 GMT)
Press Release: Khiron Reports Q2 Results, 47% QoQ -2-
The Company reported $9.4 million in cash as of June 30,2021, compared to $12.5 million in cash at the end of Q1 2021 and $21.6 million in cash at the end of 2020. On a proforma basis, the Company's Q2 2021 cash balance was $20.6 million, including estimated net proceeds from the Company's July offering.
Webcast Details
Khiron invites individual and institutional investors, as well as advisors and analysts, to attend the Company's Second Quarter 2021 Conference Call, followed by a Q&A session.
DATE: August 23, 2021
TIME: 10:00am ET/7:00am PT/4:00pm CET
PRESENTERS: Alvaro Torres, Khiron Chief Executive Officer and Director, Joel Friedman, Khiron Chief Financial Officer, Franziska Katterbach, President Khiron Europe and Chris Naprawa, Chairman of Khiron Board of Directors
FORMAT: Live 60-minute presentation & Q&A session
REGISTER LINK:
https://event.on24.com/wcc/r/3368735/FAE8C9703BB105D1B088594F064C2FCD
About Khiron Life Sciences Corp.
Khiron is a leading vertically integrated medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health centres and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in Mexico in 2021. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram @khironlife.
Khiron 2nd quarter results look good, improvements over previous Qs I like the 88% margin on prescriptions sold
Here is the link to the conference call today at 10
https://event.on24.com/wcc/r/3368735/FAE8C9703BB105D1B088594F064C2FCD
Mexico does not have religious fanatics controlling their Country.
It amazes me that Mexico is farther ahead than the USA! Here is a link to the latest email
http://6800456.hs-sites.com/khiron-investors-monthly-newsletter-1628962574441?ecid=ACsprvsuU9-bEw0o1EI5uHHkQpYD87KAg0n_JwIcC0ORaHNV-Klb8T-x6gL0jD4kzhhqOPpKmHS2&utm_medium=email&_hsmi=149852094&_hsenc=p2ANqtz--jKZ
$KHRNF I think it can only be positive. I know I will be listening carefully for any kind of guidance in future news releases, and now sure seems to be a better time to be building a stronger position than waiting for that news.
I'm curious what this news will do with Germany's sales..
''Also in Germany, the demand is around 60% flower and 40% oil. We can’t export
flower from Colombia at this time and we’re not pushing the government to allow it.''
With regard to the German cannabis market, the transaction was completed as part of a distribution agreement that Khiron has with Nimbus Health, a leading EU-GMP/GDP certified medical cannabis distributor in Germany with a network of 300+ pharmacies. Currently, Khiron’s products are located at Nimbus’ warehouse and are ready to be distributed through its network.
By 2028, the German medical cannabis market is predicted to be worth nearly €7.7bn (source: Prohibition Partners)
Hey everybody!!
Are you all also following this company on Stocktwits?
https://stocktwits.com/symbol/KHRNF
Khiron Welcomes Dr. Eduardo Faveret as Medical Director for Brazil
July 29, 2021·4 min read
In this article:
KHRNF
-2.32%
In 2013, Dr. Faveret became one of the first Brazilian physicians to prescribe medical cannabis, subsequently treating more than 3,000 patients with various conditions across the country
As Medical Director for Zerenia™, Dr. Faveret will lead patient prescriptions, physician outreach and education, and data-driven product development for Khiron in Brazil, leveraging relationships and deep medical cannabis expertise developed throughout 30-year career
Khiron positioned to expand Zerenia™ clinics in key cities in Brazil following addition of Medical Director and first sales in Brazil in early July, leveraging Brazilian marketing agreements and production, distribution, and clinical assets in Latin America
Brazil is Latin America's largest addressable market, with over 200 million people and the potential to reach USD$1.4 billion in annual revenues (Source: New Frontier Data)
TORONTO, July 29, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN)(OTCQX:KHRNF)(Frankfurt:A2JMZC), a vertically integrated medical cannabis leader with core operations in Latin America and Europe, is pleased to announce the addition of renowned physician, pediatric neurologist and clinical physiologist, Dr. Eduardo Faveret, as Medical Director for Zerenia™ Brazil. As the Company expands its global leadership position, the addition of Dr. Faveret represents a major milestone toward bringing Khiron's market validated clinic strategy to larger markets in Latin America.
Dr. Eduardo Faveret, Medical Director Zerenia™ Brazil
Dr. Faveret is a prominent advocate for medical cannabis in Brazil and a leading prescriber in the country of more than 200 million people. In 2013, Dr. Faveret became one of the first physicians in Brazil to prescribe medical cannabis extract to a child, subsequently treating more than 3,000 patients with conditions such as Alzheimer's, Parkinson's, MS, cancer, anxiety, depression, insomnia, Tourette's syndrome, autism, and chronic pain, among others.
Dr. Faveret boasts a highly distinguished medical and academic career, as the founder and former medical director of the Epilepsy Center at the Paulo Niemeyer State Brain Institute in Rio de Janeiro. He completed post-graduate studies in Pediatric Neurology (Federal University of Rio de Janeiro and FIOCRUZ) and specialized in Clinical Neurophysiology and Epileptology in Bonn Universität and Bethel Epilepsie Zentrum in Germany.
Management Commentary
Alvaro Torres, Khiron CEO and Director, commented: "We are thrilled to welcome Dr. Faveret to our team. With over eight years' experience helping patients access medical cannabis, Dr. Faveret is a leading medical cannabis specialist in Brazil who shares our mission of improving patients' lives through medical cannabis. With the goal of establishing ourselves as the dominant B2C medical cannabis company in Latin America and Europe, and having proven our ability to supply Khiron-branded product to Brazilian patients, we look forward to working with Dr. Faveret to deliver our proven vertically integrated strategy in Latin America's largest market."
About Khiron Life Sciences Corp.
Khiron is a leading vertically integrated medical cannabis company with core operations in Latin America and Europe. Leveraging wholly-owned medical health centres and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific expertise, product innovation, and agricultural infrastructure to drive prescriptions and brand loyalty with patients worldwide. The Company has a sales presence in Colombia, Peru, Germany, UK, and Brazil and is positioned to commence sales in Mexico in 2021. The Company is led by Co-founder and Chief Executive Officer, Alvaro Torres, together with an experienced and diverse executive team and Board of Directors.
Visit Khiron online at investors.khiron.ca and on Instagram @khironlife.
Everyone with a family member in north america has the opportunity to buy stock in any of the companies currently listed on the public exchange. This is the opportunity of a lifetime to secure generational wealth and security. They can invest thousands if not millions into curing their mold and strain problem or they could be the banker’s bosses and buy shares in the company. They could require to be given shares as part of their payment and then everyone is rowing in the same direction. I am glad they have folks interpreting the documents for them. The internet is a wonderful tool.
I watched it again but still saw no Khiron t shirts. I saw the cannabis network logo on a bunch of folks and it is similar to Khirons logo. It seems they are organizing and they have people who are advocating for them so if they stick together they will have a decent share. Maybe the cartels they have been working for all these years will give them the money to get their license? They are good guys right? What if they pooled their money and got a nice bunch of shares in Khiron at these few pennies a share and then they would be the banker’s bosses?! It worked for the green warriors that forced exxon to change their practices lol! There are many ways to play this.
Well that's what I was doing with those videos (examining what the company was doing down there), and I didn't much like what I saw so I quickly sold......Did you view them at all and notice how the locals viewed Khiron ?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=165214176
Khiron has been laying the ground work for a very long time. That is how successful companies do it. I do not pay attention to the share price unless I want to buy or sell. I just look at what the business is doing.
Another one of Ted OHashi's great picks and heavily promoted by him.
And to be sure... there is a lot of interest in this company.
$KHRNF Trading activity points to serious interest, and I'm not surprised. I've been loading for a while, and it's only to be expected that many others are hoping to load in this range before the broader market becomes aware.
Yes but locals were wearing Khiron t-shirts (4 YEARS AGO).....
Yes but locals were wearing Khiron t-shirts (4 YEARS AGO).....
Many folks were wearing Khiron t-shirts (4 YEARS AGO).....
youtube.com/watch?v=7aOuiYJkGwU&list=PL6culvOP2rJsHUcTK5DVqe0f6iqUIxiU4&index=4
That is wonderful! Thank you for sharing!
$KHRNF MORE awesome news!! A great read on a Sunday morning, this news came out 5 minutes after the market closed on Friday.
https://www.reuters.com/world/americas/colombia-boosts-budding-cannabis-industry-by-removing-ban-dry-flower-exports-2021-07-23/
This, from Marijuana Moment…
“Mexico's Supreme Court published the text of its declaration of marijuana prohibition's unconstitutionality.”
https://www.dof.gob.mx/nota_detalle.php?codigo=5623991&fecha=15/07/2021
Most under-rated MJ stock in the industry IMO. Look at what Khiron has going on and at the potential. Mind blowing literally. Adding significantly down here at the silly bargain level. GL.
Well, see where it was asked THIS in a post which you replied to ?
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164916842
Thankyou! I missed it much appreciated :)
Thinking .20 we bounce?
Where DO I see support ?....C'mon ;
I posted that here yesterday :
Next Day ;
TODAY I saw support right there, but she closed below .25
So has the .25 of December 2020 failed to hold and she's headin' for The Magnet .21 ?
Or has it merely Poked-Thru the .25 and is now a bargain-price ?.....
See Whole Sector - Holy Cow !~.....Has just ripped down thru $10 !
https://bigcharts.marketwatch.com/advchart/frames/frames.asp?show=&insttype=&symb=hmmj&x=61&y=15&time=100&startdate=1%2F1%2F2020&enddate=7%2F29%2F2021&freq=1&compidx=aaaaa%3A0&comptemptext=&comp=none&ma=0&maval=9&uf=0&lf=1&lf2=0&lf3=0&type=2&style=320&size=3&timeFrameToggle=false&compareToToggle=false&indicatorsToggle=false&chartStyleToggle=false&state=9
May have to figure out where support is THERE !....Looks like there';s a gap at $8
So if/when that thing needed to fill, we'd see Khiron hit its' .21 Magnet !
Where do you see next support?
That makes sense, any time a company does a capital raise their stock takes a hit. Good find. They will need some funds to continue building in Mexico :)
Awww, sorry, I'm terrible at that. Y'mean warrants exercisable, etc. yeah/no....
Seems like there might be though, now that y'mention it.
Or wait - No ; What's all this :
Khiron Life Sciences slips on announcing terms of securities offering
https://seekingalpha.com/news/3712969-khiron-life-sciences-slips-on-announcing-terms-of-securities-offering?utm_source=advfn.com&utm_medium=referral
Anyone know of any lock up timeframes for early investors?
They did a capital raise. That will drop the price. It is just a fact of life when a company is just starting up. This company is expanding so it can sell what they grow in Columbia in their clinics across LATAM a company can only make money if it raises capital or sells a profitable product. Their product will be profitable but the indstry is so new they have to invest in the infrastructure to support it. Mexico is opening up and I am good with them raising money to build more clinics there.
Wtf happened over here? Didnt have much but dang it moved to the bottom of my holdings on the value.
Khiron is probably the most under-estimated / appreciated / valued MJ play out there. Bold statement from an investor who has in fact invested in multi multi MJ companies in recent years. I predict big things (and returns). Long and strong (for real).
I am glad to see another country opening up!
https://www.instagram.com/tv/CRCZDEZH-8f/?utm_medium=copy_link
The Great Khiron Death Nail (and all that surrounds it).....
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=164757947
Dropped .06 as expected if math serves w value of warrants etc
Expansion in Mexico?
My guess this will be used for rapid expansion.
Khiron Life Sciences Announces Terms of Overnight Marketed Offering
https://money.tmx.com/en/quote/KHRNF:US/news/6660095763378777/Khiron_Life_Sciences_Announces_Terms_of_Overnight_Marketed_Offering
Followers
|
60
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2405
|
Created
|
06/10/18
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |